Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
BASHH welcomes publication of position statement on doxycycline as post-exposure prophylaxis for sexually transmitted infections

The British Association for Sexual Health and HIV (BASHH) has welcomed the publication of a new joint BASHH and Public Health England (PHE) position statement on the use of doxycycline as post-exposure prophylaxis (PEP) for sexually transmitted infections (STIs). A conference presentation had suggested that use of PEP with doxycycline was associated with a halving of the rates of bacterial STIs in men who have sex with men (MSM), in an extension of the French IPERGAY trial. However caution is advised.

Published
03 November 2017
From
BASHH
GSK and Gilead go head to head as HIV drugs enter new phase

Gilead Sciences and GlaxoSmithKline are heading for an HIV showdown, pushing rival treatment visions and competing products that are expected to hit the market in the next few months. Gilead is likely to secure the bigger near-term win, as it builds on a 20-year-old strategy of combining three drugs to control the AIDS virus, while GSK is placing a longer bet that its core drug is potent enough to work with just one other.

Published
02 November 2017
From
Reuters
Betty Price's HIV Quarantine Query Echoes White Supremacist Voices in the Trump Era

Price's line of questioning seemed to belong to the 1980s, when HIV and AIDS were less understood and far less preventable, as well as surrounded by much more fear and hysteria. But I heard very similar consideration of quarantining people with HIV as a viable option a few months ago -- on a white supremacist podcast. And these podcasts are the new "test kitchens" of the right -- floating ideas once considered politically impossible to see what'll stick with the core supporters of the current regime.

Published
01 November 2017
From
The Body
DC biohackers and blockchainers take on HIV

Tristan Roberts tested a treatment for HIV by self-injecting. Next, Ascendance Biomedical plans to share over the blockchain. It's being done outside the FDA's regulatory process, and a bioethicist has concerns.

Published
01 November 2017
From
Technical.ly DC
Uganda: ARVs Stock-Out Sparks Fear of Mass Drug Resistance

Civil society organisations and people living with HIV/Aids have warned that almost a million Ugandans could develop resistance to first-line anti-retroviral therapy if nothing is done about the nation-wide stock-out of drugs.

Published
01 November 2017
From
AllAfrica
European HIV Guidelines Make Special HPV Recommendations for Gay Men

Gay and bisexual men with HIV should get vaccinated for human papillomavirus (HPV) up until age 40, according to updated guidelines from the European AIDS Clinical Society (EACS), released this week at the 16th European AIDS Conference. And others with HIV should be vaccinated until age 26, the guidelines state.

Published
30 October 2017
From
Medscape (requires free registration)
ViiV Survey Reveals Nuances of Living With HIV

Respondents reported on their feelings about antiretrovirals, their relationships with their clinicians and dealing with stigma.

Published
30 October 2017
From
Poz
Symtuza as effective as multi-pill combination in previously untreated people with HIV

The single-pill combination of darunavir, cobicistat, tenofovir alafenamide and emtricitabine (Symtuza) is just as effective as a multi-pill combination of darunavir, cobicistat, emtricitabine and the older formulation of

Published
28 October 2017
By
Keith Alcorn
Fostemsavir controls viral load in half of people with highly drug-resistant HIV

Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance

Published
28 October 2017
By
Keith Alcorn
People with HIV still expect a lower quality of life than their negative peers, European survey finds

A study commissioned by the drug company Gilead Sciences and conducted in five European countries has found that, compared with their HIV-negative peers, people with HIV still

Published
27 October 2017
By
Gus Cairns

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.